全球 Xgeva 市场按适应症、年龄层、销售管道、最终用户和地区划分

预计 2025 年全球 Xgeva 市场规模为 22.721 亿美元，2032 年将达到 31.407 亿美元，2025 年至 2032 年的复合年增长率为 2.7%。

Xgeva 的全球市场代表製药业的一个重要领域，主要集中在基于Denosumab的疗法，用于治疗癌症患者的骨相关併发症。 Xgeva（Denosumab）是一种人源单株抗体，作为 RANK 配体抑制剂，可有效预防固体癌骨转移患者的骨骼相关事件，并治疗骨鉅细胞瘤。由于全球癌症发生率的不断上升以及人们对癌症治疗中骨骼健康管理的认识不断提高，这一专业治疗领域正受到广泛关注。

这个市场拥有各种各样的相关人员，包括製药商、医疗保健提供者、经销商和监管机构，所有这些都构成了围绕这一重要药物的复杂生态系统。随着全球医疗保健系统将全面的癌症治疗放在首位，对像Xgeva这样的有效骨骼保护疗法的需求持续增长。市场动态受到监管部门核准、新兴临床证据、定价压力以及生物相似药替代品的出现等因素的影响。了解全球Xgeva市场的复杂格局对于製药公司、医疗保健投资者和医疗专业人员来说至关重要，他们正试图探索癌症治疗方案中不断变化的骨骼併发症治疗方案。

市场动态

Xgeva 全球市场成长的关键驱动力在于全球癌症发生率的上升，这是由于固体癌数量不断增加，而这些实体瘤通常会转移到骨骼，从而对有效的骨保护疗法产生了巨大的需求。此外，Denosumab的适应症已从骨转移扩展到骨鉅细胞瘤和其他骨骼疾病，从而持续扩大了可及的患者群体。已开发地区医疗基础设施的建设以及癌症专科治疗可近性的提高，进一步推动了市场的成长。

然而，市场面临着许多限制因素，包括高昂的治疗费用限制了药物的可近性，尤其是在价格敏感型市场和医疗预算受限的新兴经济体。长期使用Denosumab的安全隐患以及潜在的副作用，例如下颚骨坏死和非典型骨折，可能会导致製剂设计师犹豫不决，并面临监管审查，从而阻碍市场扩张。此外，替代生物相似药的出现也为安加维 (Xgeva) 品牌产品带来了定价压力和市场占有率流失风险。儘管存在这些挑战，但仍存在着巨大的机会，例如透过持续的研发活动扩大临床应用、与新型癌症疗法的潜在联合治疗以及向医疗保健可及性不断改善的未开发市场进行地域扩张。对个人化医疗和生物标记指导的治疗选择的日益关注，为市场增长提供了更多机会，而製药公司和医疗保健提供者之间的战略伙伴关係则有可能提升市场渗透率和患者可及性。

本次调查的主要特点

• 本报告对全球 Xgeva 市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。
• 它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的主要考察。
• 它根据公司亮点、产品系列、关键亮点、业绩和策略等参数对全球 Xgeva 市场的主要企业进行了概述。
• 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、最新策略、市场扩张和行销策略做出明智的决策。
• Xgeva 的全球市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 透过全球 Xgeva 市场分析中使用的各种策略矩阵，相关人员可以轻鬆做出决策。

目录

第一章：调查目标和先决条件

• 调查目的
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章：市场动态、法规与趋势分析

• 市场动态
• 驱动程式
• 抑制因素
• 机会
• 影响分析
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景
• 产业趋势
• 流行病学

4. 全球 Xgeva 市场（依适应症划分），2020 年至 2032 年

• 介绍
• 固态肿瘤骨转移
• 骨鉅细胞瘤
• 双磷酸盐抗药性癌症相关高血钙症

5. 2020 年至 2032 年按年龄分類的全球 Xgeva 市场

• 介绍
• 成人
• 老年人
• 青年

6. 全球 Xgeva 市场依销售管道划分，2020 年至 2032 年

• 介绍
• 在线的
• 离线

7. 全球 Xgeva 市场（以最终用户划分），2020 年至 2032 年

• 介绍
• 医院
• 肿瘤中心
• 復健中心
• 其他（护理设施等）

8. 2020 年至 2032 年全球 Xgeva 市场（按地区划分）价值（百万美元）

• 介绍
• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 东南亚国协
  • 其他亚太地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
• 非洲
  • 南非
  • 北非
  • 中部非洲

第九章 竞争态势

• Amgen Inc.
• BeOne Medicines, Ltd, formerly known as BeiGene, Ltd.

第 10 章分析师建议

• 机会
• 一致的机会地图

第 11 章参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Global Xgeva Market is estimated to be valued at USD 2,272.1 Mn in 2025 and is expected to reach USD 3,140.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 2.7% from 2025 to 2032.

The global Xgeva market represents a critical segment within the pharmaceutical industry, focusing on denosumab-based therapeutics primarily used for bone-related complications in cancer patients. Xgeva (denosumab) is a human monoclonal antibody that functions as a RANK ligand inhibitor, effectively preventing skeletal-related events in patients with bone metastases from solid tumors and treating giant cell tumor of bone. This specialized therapeutic area has garnered significant attention due to the increasing prevalence of cancer worldwide and the growing recognition of bone health management in oncology care.

The market encompasses various stakeholders, including pharmaceutical manufacturers, healthcare providers, distributors, and regulatory bodies, all contributing to the complex ecosystem surrounding this vital medication. As healthcare systems globally prioritize comprehensive cancer care, the demand for effective bone protection therapies like Xgeva continues to expand. The market dynamics are influenced by factors such as regulatory approvals, clinical evidence generation, pricing pressures, and the emergence of biosimilar alternatives. Understanding the intricate landscape of the Global Xgeva Market is essential for pharmaceutical companies, healthcare investors, and medical professionals seeking to navigate the evolving therapeutic options for bone complications in cancer treatment protocols.

Market Dynamics:

The global Xgeva market growth is primarily driven by the escalating global cancer burden, with increasing incidences of solid tumors that frequently metastasize to bone, creating substantial demand for effective bone protection therapies. The growing awareness among oncologists and healthcare providers regarding the importance of preventing skeletal-related events has significantly boosted market adoption, while expanding indications for denosumab beyond bone metastases to include giant cell tumor of bone and other bone disorders continues to broaden the addressable patient population. Advanced healthcare infrastructure in developed regions and improving access to specialty cancer care in emerging markets further propel market growth.

However, the market faces considerable restraints, including the high cost of treatment, which limits accessibility, particularly in price-sensitive markets and developing economies where healthcare budgets are constrained. Safety concerns and potential adverse effects associated with long-term denosumab use, including osteonecrosis of the jaw and atypical fractures, create prescriber hesitancy and regulatory scrutiny that can impede market expansion. Additionally, the emergence of biosimilar alternatives poses pricing pressure and market share erosion risks for branded Xgeva products. Despite these challenges, significant opportunities exist in the form of expanding clinical applications through ongoing research and development activities, potential combination therapies with emerging cancer treatments, and geographical expansion into underserved markets with improving healthcare access. The increasing focus on personalized medicine and biomarker-driven treatment selection presents additional avenues for market growth, while strategic partnerships between pharmaceutical companies and healthcare providers can enhance market penetration and patient access programs.

Key features of the study:

• This report provides an in-depth analysis of the global Xgeva market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Xgeva market based on the following parameters: company highlights, product portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amgen Inc. and BeOne Medicines, Ltd, formerly known as BeiGene, Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Xgeva market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Xgeva market

Market Segmentation

• Indication Insights (Revenue, USD Mn, 2020 - 2032)
  • Bone Metastasis from Solid Tumors
  • Giant Cell Tumor of Bone
  • Hypercalcemia of malignancy refractory to bisphosphonates
• Age Group Insights (Revenue, USD Mn, 2020 - 2032)
  • Adult
  • Geriatric
  • Adolescents
• Sales Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Online
  • Offline
• End User Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospitals
  • Oncology Centers
  • Rehabilitation Centers
  • Others (Long-Term Care Facilities, etc.)
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Amgen Inc.
  • BeOne Medicines, Ltd, formerly known as BeiGene, Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Xgeva Market, By Indication
  • Global Xgeva Market, By Age Group
  • Global Xgeva Market, By Sales Channel
  • Global Xgeva Market, By End User
  • Global Xgeva Market, By Region

3. Market Dynamics, Regulations, And Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends
• Epidemiology
  • Adherence
  • Persistence

4. Global Xgeva Market, By Indication, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Bone Metastasis from Solid Tumors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Giant Cell Tumor of Bone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Hypercalcemia of malignancy refractory to bisphosphonates
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Xgeva Market, By Age Group, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Adolescents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Xgeva Market, By Sales Channel, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Online
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Offline
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Xgeva Market, By End User, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Oncology Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Rehabilitation Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others (Long-Term Care Facilities, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Xgeva Market, By Region, 2020 - 2032, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BeOne Medicines, Ltd, formerly known as BeiGene, Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us